Editorial: health-related complications of acromegaly

Editorial on the Research Topic
Health-Related Complications of Acromegaly

Acromegaly is a chronic disease mostly caused by a growth hormone (GH)-secreting pituitary adenoma. Excessive GH and insulin-like growth factor I (IGF-I) secretion in acromegaly promote tissues overgrowth, appearance changes, musculoskeletal disorders, and metabolic complications, which result in poor quality of life, increased mortality and decreased longevity when the disease is not adequately controlled ( 1 , 2 ). Main causes of premature mortality in active acromegaly are cardiovascular, respiratory and neoplastic diseases ( 3 5 ), which are influenced by the concomitant presence of arterial hypertension, cardiomyopathy, arrhythmias, diabetes mellitus, and unfavorable lipid profile ( 2 , 6 ).

The purpose of this special issue on health-related complications of acromegaly is to review the most common and jeopardizing comorbidities associated with the disease, since early diagnosis and optimal management of acromegaly and its comorbidities are critical to ensure best long-term outcomes.

2. Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab.(2020) 105: dgz096. doi: 10. 1210/clinem/dzg096

3. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab.(2004) 89: 667–74. doi: 10. 1210/jc. 2003-031199

4. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab.(2008) 93: 61–7. doi: 10. 1210/jc. 2007-1191

5. Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS. Mortality in acromegaly decreased in the last decade: a systematic review and metaanalysis. Eur J Endocrinol.(2018) 179: 59–71. doi: 10. 1530/EJE-18-0255

6. Abreu A, Tovar AP, Castellanos R, Valenzuela A, Gomez Giraldo CM, Pinedo AC, et al. Challenges in the diagnosis and management: a focus on comorbodities. Pituitary.(2016) 19: 448–57. doi: 10. 1007/s11102-016-0725-2

7. Sardella C, Urbani C, Lombardi M, Nuzzo A, Manetti L, Lupi I, et al. The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin Endocrinol.(2014) 81: 573–81. doi: 10. 1111/cen. 12455

8. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, García-Dominguez A, Reza-Albarrán AA, et al. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab.(2016) 101: 3997–4004. doi: 10. 1210/jc. 2016-1937

9. Minniti G, Moroni C, Jaffrain-Rea ML, Esposito V, Santoro A, Affrican C, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol.(2001) 55: 307–13. doi: 10. 1046/j. 1365-2265. 2001. 01343. x

10. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly, a head-to-head superiority study. J Clin Endocrinol Metab.(2014) 99: 791–9. doi: 10. 1210/jc. 2013-2480

11. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA), a randomised, phase 3 trial. Lancet Diabetes Endocrinol.(2014) 2: 875–84. doi: 10. 1016/S2213-8587(14)70169-X

12. Fleseriu M, Rusch E, Geer EB, on behalf of the ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine.(2017) 55: 247–55. doi: 10. 1007/s12020-016-1182-4

13. Roelfsema F, Frolich M. Glucose tolerance and plasma immunoreactive insulin levels in acromegalics before and after selective transsphenoidal surgery. Clin Endocrinol.(1985) 22: 531–7. doi: 10. 1111/j. 1365-2265. 1985. tb00153. x

14. Ferrau F, Albani A, Ciresi A, Giordano C, Cannavo S. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol.(2018) 9: 358. doi: 10. 3389/fendo. 2018. 00358

15. Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G, et al. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab.(2009)94: 2907–14. doi: 10. 1210/jc. 2008-2627

16. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab.(2005)90: 5627–31. doi: 10. 1210/jc. 2005-0531

17. Ferns GA, Motani AS, Anggård EE. The insulin-like growth factors: their putative role in atherogenesis. Artery.(1991) 18: 197–225.

18. Tellatin S, Maffei P, Osto E, Dassie F, Famoso G, Montisci R, et al. Coronary microvascular dysfunction may be related to IGF-1 in acromegalic patients and can be restored by therapy. Atherosclerosis.(2018) 269: 100–5. doi: 10. 1016/j. atherosclerosis. 2017. 12. 019

19. Dal J, Leisner MZ, Hermansen K, Farkas DK, Bengtsen M, Kistorp C, et al. Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. J Clin Endocrinol Metab.(2018) 103: 2182–8. doi: 10. 1210/jc. 2017-02457

20. Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol.(2008) 14: 3484–9. doi: 10. 3748/wjg. 14. 3484

21. Kunzler LS, Araujo TCCF. Cognitive therapy: using a specific technique to improve quality of life and health. Estudos Psicol.(2013)30: 267–74. doi: 10. 1590/S0103-166X2013000200013

22. Kužma M, Vaňuga P, Ságová I, Pávai D, Jackuliak P, Killinger Z, et al. Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol.(2019)180: 201–11. doi: 10. 1530/EJE-18-0881